# Boehringer Ingelheim and Microsoft aim to develop AI-backed digital patient twins

Digest AI · Research · published 2026-10-21T15:30:00Z

Canonical: https://digestai.news/story/boehringer-ingelheim-and-microsoft-aim-to-develop-ai-backed-digital-pa

## Summary

Boehringer Ingelheim and Microsoft announced a strategic collaboration to explore AI‑enabled digital patient twins that model individual patients using clinical and other relevant data. The partners said the work will focus on disease‑progression modelling, predictive outcome modelling, and advanced trial simulation, including synthetic or hybrid control arms that combine existing data with conventional groups.

The joint research will start with lung health and will assess scientific and technical feasibility through modelling, prototyping and evidence generation across multiple disease and therapeutic areas. Both companies stress that scientific quality, patient safety and regulatory requirements must be upheld throughout the effort. Agnes Heftberger, corporate vice‑president and CEO of Microsoft Germany and Austria, said the partnership brings together pharmaceutical expertise with Microsoft’s AI capabilities. Boehringer Ingelheim’s chief medical officer, Dr. Lykke Hinsch Gylvin, added that the aim is to make clinical research more patient‑centric, responsive and efficient.

If successful, the collaboration could reduce the number of patients needed in control groups, speed evidence generation and improve trial design, potentially getting innovative medicines to patients sooner.

## Key points

- Boehringer Ingelheim and Microsoft announced a strategic collaboration to explore AI‑enabled digital patient twins for clinical development.
- The joint research will investigate disease‑progression modelling, predictive outcome modelling, and synthetic or hybrid trial control arms, starting with lung health.
- The partnership aims to reduce control‑group sizes, speed evidence generation, and improve trial design while maintaining safety and regulatory compliance.

## Why it matters

Digital patient twins could cut trial participant numbers and accelerate drug development, helping patients receive new therapies faster and reshaping pharmaceutical research practices.

## Sources

1. [Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development](https://finance.yahoo.com/healthcare/articles/boehringer-ingelheim-microsoft-partner-drive-113000273.html) (finance.yahoo.com, 2026-10-21)

## Cite

Digest AI, "Boehringer Ingelheim and Microsoft aim to develop AI-backed digital patient twins", 21 October 2026, https://digestai.news/story/boehringer-ingelheim-and-microsoft-aim-to-develop-ai-backed-digital-pa

---

Written by Digest AI's editorial model from the linked sources; the sources are the record. Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse
JSON: https://digestai.news/story/boehringer-ingelheim-and-microsoft-aim-to-develop-ai-backed-digital-pa.json